Other

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Université Paris Descartes

Université Paris Diderot-paris 7

Retroperfusion Systems, Inc.

Pasteur Merieux Serums Et Vaccines

Bioetica

Universite Paris Cité

Inserm (institut National De La Sante Et De La Recherche Medicale)

Université Montpellier 2 Sciences Et Techniques

Alain Huc

Philippe Menasche

Herve Petite

Alain Roger Huc

Jérôme Larghero

Guillaume Blin

David Nury

Sonia Stefanovic

Michel Puceat

Nisa Renault

Valérie Bellamy

Laetitia Pidial

Jerome Larghero

The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.

Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications

Perfusion and preservation and/or reperfusion solutions for surgery and organ transplantation, including that of the heart, a feature of which solutions is the inclusion of at least one antioxidant compound, such as a trapping agent for free oxygen radicals, in particular glutathione in the reduced state or N-acetylcysteine, said solutions possessing a zero or greatly reduced partial pressure of oxygen which is maintained substantially at this value up to the time of use. The solution is preferably presented in flexible bags impermeable to oxygen.

Solutions for the perfusion, preservation and reperfusion of organs

Process for cross-linking of collagen by diphenylphosphorylazide the

This process, which essentially comprises the following steps:

Process for crosslinking of collagen by introduction of azide groups as

A coronary sinus catheter having a flexible elongate member with proximal and distal extremities. The flexible elongate member has at least two lumens extending longitudinally thereof. A balloon is mounted on the distal extremity of the flexible elongate member and has its interior in communication with one of the lumens. The balloon has at least one truncated conical surface with outwardly facing spaced apart parallel concentric lands formed thereon for frictionally engaging the coronary sinus to provide a high retentive force for the catheter.

Coronary sinus catheter

Growing community of inventors

Paris, France

Philippe Menasche